C. Saint-Laurent

Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia

J. Salles, P. Gual, A. Tran, 2018, PloS one.

The Tyrosine Phosphatase SHP2: A New Target for Insulin Resistance?

I. Castan-Laurell, C. Dray, P. Valet, 2022, Biomedicines.

Obesity in achondroplasia patients: from evidence to medical monitoring

E. Gouze, Céline Saint-Laurent, C. Saint-Laurent, 2019, Orphanet Journal of Rare Diseases.

SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations

P. Froguel, B. Neel, M. Canouil, 2021, Science Translational Medicine.

Enhanced glucose metabolism is preserved in cultured primary myotubes from obese donors in response to exercise training.

D. Langin, C. Moro, Pierre-Marie Badin, 2013, The Journal of clinical endocrinology and metabolism.

Second Bonn Challenge progress report: application of the Barometer in 2018

S. Simonit, Lara Murray, G. Daldegan, 2019 .

Novel therapeutic perspectives in Noonan syndrome and RASopathies

A. Yart, Céline Saint-Laurent, C. Saint-Laurent, 2023, European journal of pediatrics.